Biological Safety Cabinet Market by Type (Class I, Class II (Type A, Type B), Class III), End User (Pharmaceutical & Biopharmaceutical Companies, Diagnostic & Testing Laboratories, Academic Research Institutes), and Region - Global Forecast to 2027
The global biological safety cabinet market is projected to reach USD0.4billion by 2027 from USD0.2billion in 2022, at a CAGR of 8.2% during the forecast period. Market growth is driven by factors such as increased production of biosimilar products and increased research for vaccines. On the other hand, challenges associated with biological safety cabinet is alternative containment cabinets is the major factors hampering the growth of this market.
“The class II segment accounted for the highest growth rate in the biological safety cabinet market, by type, during the forecast period”
The biological safety cabinet market is segmented into class I, class II and class III. In 2021, class II segment accounted for the highest growth rate in the biological safety cabinet market. Growing pharmaceutical and biopharmaceutical industry and growing concerns over cell culture contamination are major factor contributing to the growth of this segment.
“The pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market, by enduser, during the forecast period”
The biological safety cabinet market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and testing laboratories and academic research institutes based on type of waste. In 2021, the pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.
“Asia Pacific: The fastest-growing region in biological safety cabinet market”
The global biological safety cabinet market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of biosafety is driving the growth of the biological safety cabinet market in this region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global biological safety cabinetmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biological safety cabinet market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints and opportunities.
“The class II segment accounted for the highest growth rate in the biological safety cabinet market, by type, during the forecast period”
The biological safety cabinet market is segmented into class I, class II and class III. In 2021, class II segment accounted for the highest growth rate in the biological safety cabinet market. Growing pharmaceutical and biopharmaceutical industry and growing concerns over cell culture contamination are major factor contributing to the growth of this segment.
“The pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market, by enduser, during the forecast period”
The biological safety cabinet market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and testing laboratories and academic research institutes based on type of waste. In 2021, the pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.
“Asia Pacific: The fastest-growing region in biological safety cabinet market”
The global biological safety cabinet market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of biosafety is driving the growth of the biological safety cabinet market in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
- Thermo Fisher Scientific (US)
- Kewaunee Scientific (US)
- Labconco (US)
- Esco Micro (Singapore)
- The Baker Company (US)
- NuAire (US)
- Germfree Laboratories (US)
- Cruma (Spain)
- Air Science (US)
- Berner International (US)
- Azbiltelstar (Spain)
- LaboGene (Denmark)
- Biolab Scientific (Canada)
- Lamsystems (Germany)
- Faster S.R.L (Italy)
- MRC Laboratory Equipment (Israel)
- Nanbei Instrument Limited (China)
- Thermolab (India)
- Labmate (UK)
- TopAir Systems, Inc. (US)
- Albian Group (Spain)
- Thomas Scientific (US)
- Zhejiang FUXIA Medical Technology Co. (China)
- Stericox (India)
This report provides a detailed picture of the global biological safety cabinetmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biological safety cabinet market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints and opportunities.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 BIOLOGICAL SAFETY CABINETS MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 BIOLOGICAL SAFETY CABINETS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 BIOLOGICAL SAFETY CABINETS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
FIGURE 8 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 10 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 BIOLOGICAL SAFETY CABINETS MARKET OVERVIEW
FIGURE 11 INCREASED RISK OF PANDEMICS AND COMMUNICABLE
DISEASES TO DRIVE MARKET
4.2 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 12 CLASS II SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 13 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES—LARGEST END USERS OF BIOLOGICAL SAFETY CABINETS
4.4 BIOLOGICAL SAFETY CABINETS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH IN FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 BIOLOGICAL SAFETY CABINETS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Favorable regulations
5.2.1.2 Increased risk of pandemics and communicable diseases
5.2.1.3 Increasing number of R&D activities in pharmaceutical and biopharmaceutical companies
FIGURE 16 R&D SPENDING BY PHRMA MEMBER COMPANIES, 2001–2019 (USD BILLION)
TABLE 1 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2019 VS. 2026 (USD BILLION)
5.2.1.4 Rapid growth in biologics
FIGURE 17 TOTAL NUMBER OF NEW BIOLOGICS LICENSE APPLICATION APPROVALS, NDA APPROVALS, AND FILINGS (2005–2019)
TABLE 2 US: LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS, 2019
5.2.1.5 Growing concerns over cell culture contamination
5.2.2 RESTRAINTS
5.2.2.1 Alternative containment cabinets
5.2.2.2 High cost of biological safety cabinets
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets offer lucrative growth opportunities
5.3 PRICING ANALYSIS
TABLE 3 PRICE OF BIOLOGICAL SAFETY CABINETS (2021)
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS OF BIOLOGICAL SAFETY CABINETS MARKET
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF BIOLOGICAL SAFETY CABINETS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 BIOLOGICAL SAFETY CABINETS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 21 BIOLOGICAL SAFETY CABINETS MARKET: ECOSYSTEM/MARKET MAP
TABLE 4 BIOLOGICAL SAFETY CABINETS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 BIOLOGICAL SAFETY CABINETS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY LANDSCAPE
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR LABORATORY MACHINERY AND EQUIPMENT
TABLE 11 IMPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 12 EXPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 13 BIOLOGICAL SAFETY CABINETS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
FIGURE 22 REVENUE SHIFT IN BIOLOGICAL SAFETY CABINETS MARKET
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINETS (%)
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS
TABLE 15 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS
5.15 CASE STUDIES
5.15.1 CASE STUDY: LABORATORY BIOLOGICAL SAFETY CABINET (BSC) EXPLOSION
6 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 16 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 17 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (THOUSAND UNITS)
6.2 CLASS I
6.2.1 GOVERNMENT INITIATIVES TO DRIVE MARKET
TABLE 18 CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 CLASS II
TABLE 19 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 20 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 CLASS II TYPE A
6.3.1.1 Increased usage of Class II Type A biosafety cabinets in laboratories to support market growth
TABLE 21 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 CLASS II TYPE B
6.3.2.1 Class II Type B cabinets used for volatile and toxic chemicals
TABLE 22 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 CLASS III
6.4.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 23 CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
7 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER
7.1 INTRODUCTION
TABLE 24 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
7.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
7.2.1 INCREASING R&D EXPENDITURE ENABLES COMPANIES TO INVEST IN HIGH-END BIOSAFETY CABINETS
TABLE 25 BIOLOGICAL SAFETY CABINETS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
7.3 DIAGNOSTIC AND TESTING LABORATORIES
7.3.1 RISING PREVALENCE OF DISEASES TO SUPPORT MARKET GROWTH
TABLE 26 BIOLOGICAL SAFETY CABINETS MARKET FOR DIAGNOSTIC AND TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
7.4 ACADEMIC RESEARCH INSTITUTES
7.4.1 INCREASING NUMBER OF RESEARCH ACTIVITIES AND RISING GOVERNMENT FUNDING FOR MEDICAL RESEARCH TO SUPPORT MARKET GROWTH
TABLE 27 BIOLOGICAL SAFETY CABINETS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
8 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION
8.1 INTRODUCTION
TABLE 28 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET SNAPSHOT
TABLE 29 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Growth in biosimilars market to boost preclinical research
TABLE 33 US: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 34 US: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 35 US: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Government support for R&D to support market growth
TABLE 36 CANADA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 CANADA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 38 CANADA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 39 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 42 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Increased funding and growth of research sector to drive market
TABLE 43 GERMANY: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 GERMANY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 GERMANY: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Increasing awareness about safety in high-risk environments to propel market
TABLE 46 UK: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 UK: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 UK: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing healthcare industry to provide growth opportunities
TABLE 49 FRANCE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 FRANCE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 FRANCE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.4 REST OF EUROPE
TABLE 52 REST OF EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 REST OF EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 REST OF EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET SNAPSHOT
TABLE 55 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Largest market for biological safety cabinets in Asia Pacific
TABLE 59 JAPAN: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 JAPAN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 JAPAN: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Government initiatives in drug development to support market growth
TABLE 62 CHINA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 CHINA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 CHINA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Growing pharmaceutical industry to drive market
TABLE 65 INDIA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 INDIA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 INDIA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 68 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 69 REST OF ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 FAVORABLE GOVERNMENT POLICIES AND INCREASING DEMAND FOR NEW DRUG MOLECULES—KEY FACTORS DRIVING MARKET
TABLE 71 LATIN AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 LATIN AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 LATIN AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST AND AFRICA
8.6.1 INCREASING R&D INVESTMENTS AND FOCUS ON DEVELOPMENT OF NEW DRUGS TO DRIVE MARKET
TABLE 74 MIDDLE EAST AND AFRICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET
TABLE 77 OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOLOGICAL SAFETY CABINET MANUFACTURING COMPANIES
9.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET
9.4 MARKET SHARE ANALYSIS
FIGURE 28 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 78 BIOLOGICAL SAFETY CABINETS MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT
9.5.1 LIST OF EVALUATED VENDORS
9.5.2 STARS
9.5.3 EMERGING LEADERS
9.5.4 PERVASIVE PLAYERS
9.5.5 PARTICIPANTS
FIGURE 29 BIOLOGICAL SAFETY CABINETS MARKET:
COMPETITIVE LEADERSHIP MAPPING, 2021
9.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
FIGURE 30 BIOLOGICAL SAFETY CABINETS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
9.7 COMPETITIVE BENCHMARKING
9.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET
TABLE 79 BIOLOGICAL SAFETY CABINETS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 80 PRODUCT FOOTPRINT OF COMPANIES
TABLE 81 REGIONAL FOOTPRINT OF COMPANIES
TABLE 82 BIOLOGICAL SAFETY CABINETS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
9.8 COMPETITIVE SCENARIO
9.8.1 PRODUCT LAUNCHES
TABLE 83 KEY PRODUCT LAUNCHES
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS
10.1.1 THERMO FISHER SCIENTIFIC
TABLE 84 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.2 KEWAUNEE SCIENTIFIC
TABLE 85 KEWAUNEE SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 33 KEWAUNEE SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.3 LABCONCO
TABLE 86 LABCONCO: BUSINESS OVERVIEW
10.1.4 ESCO MICRO
TABLE 87 ESCO MICRO: BUSINESS OVERVIEW
10.1.5 THE BAKER COMPANY
TABLE 88 THE BAKER COMPANY: BUSINESS OVERVIEW
10.1.6 NUAIRE
TABLE 89 NUAIRE: BUSINESS OVERVIEW
10.1.7 GERMFREE LABORATORIES
TABLE 90 GERMFREE LABORATORIES: BUSINESS OVERVIEW
10.1.8 CRUMA
TABLE 91 CRUMA: BUSINESS OVERVIEW
10.1.9 AIR SCIENCE
TABLE 92 AIR SCIENCE: BUSINESS OVERVIEW
10.1.10 BERNER INTERNATIONAL
TABLE 93 BERNER INTERNATIONAL: BUSINESS OVERVIEW
10.1.11 AZBIL TELSTAR
TABLE 94 AZBIL TELSTAR: BUSINESS OVERVIEW
10.1.12 LABOGENE
TABLE 95 LABOGENE: BUSINESS OVERVIEW
10.1.13 BIOLAB SCIENTIFIC
TABLE 96 BIOLAB SCIENTIFIC: BUSINESS OVERVIEW
10.1.14 LAMSYSTEMS GMBH
TABLE 97 LAMSYSTEMS GMBH: BUSINESS OVERVIEW
10.1.15 FASTER S.R.L.
TABLE 98 FASTER S.R.L.: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 MRC LABORATORY EQUIPMENT
TABLE 99 MRC LABORATORY EQUIPMENT: COMPANY OVERVIEW
10.2.2 NANBEI INSTRUMENT LIMITED
TABLE 100 NANBEI INSTRUMENT LIMITED: COMPANY OVERVIEW
10.2.3 THERMOLAB
TABLE 101 THERMOLAB: COMPANY OVERVIEW
10.2.4 LABMATE
TABLE 102 LABMATE: COMPANY OVERVIEW
10.2.5 TOPAIR SYSTEMS, INC.
TABLE 103 TOPAIR SYSTEMS, INC.: COMPANY OVERVIEW
10.2.6 ALBIAN GROUP
TABLE 104 ALBIAN GROUP: COMPANY OVERVIEW
10.2.7 THOMAS SCIENTIFIC
TABLE 105 THOMAS SCIENTIFIC: COMPANY OVERVIEW
10.2.8 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.
TABLE 106 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
10.2.9 STERICOX
TABLE 107 STERICOX: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 BIOLOGICAL SAFETY CABINETS MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 BIOLOGICAL SAFETY CABINETS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 BIOLOGICAL SAFETY CABINETS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
FIGURE 8 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 10 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 BIOLOGICAL SAFETY CABINETS MARKET OVERVIEW
FIGURE 11 INCREASED RISK OF PANDEMICS AND COMMUNICABLE
DISEASES TO DRIVE MARKET
4.2 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 12 CLASS II SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 13 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES—LARGEST END USERS OF BIOLOGICAL SAFETY CABINETS
4.4 BIOLOGICAL SAFETY CABINETS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH IN FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 BIOLOGICAL SAFETY CABINETS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Favorable regulations
5.2.1.2 Increased risk of pandemics and communicable diseases
5.2.1.3 Increasing number of R&D activities in pharmaceutical and biopharmaceutical companies
FIGURE 16 R&D SPENDING BY PHRMA MEMBER COMPANIES, 2001–2019 (USD BILLION)
TABLE 1 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2019 VS. 2026 (USD BILLION)
5.2.1.4 Rapid growth in biologics
FIGURE 17 TOTAL NUMBER OF NEW BIOLOGICS LICENSE APPLICATION APPROVALS, NDA APPROVALS, AND FILINGS (2005–2019)
TABLE 2 US: LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS, 2019
5.2.1.5 Growing concerns over cell culture contamination
5.2.2 RESTRAINTS
5.2.2.1 Alternative containment cabinets
5.2.2.2 High cost of biological safety cabinets
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets offer lucrative growth opportunities
5.3 PRICING ANALYSIS
TABLE 3 PRICE OF BIOLOGICAL SAFETY CABINETS (2021)
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS OF BIOLOGICAL SAFETY CABINETS MARKET
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF BIOLOGICAL SAFETY CABINETS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 BIOLOGICAL SAFETY CABINETS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 21 BIOLOGICAL SAFETY CABINETS MARKET: ECOSYSTEM/MARKET MAP
TABLE 4 BIOLOGICAL SAFETY CABINETS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 BIOLOGICAL SAFETY CABINETS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY LANDSCAPE
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR LABORATORY MACHINERY AND EQUIPMENT
TABLE 11 IMPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 12 EXPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 13 BIOLOGICAL SAFETY CABINETS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
FIGURE 22 REVENUE SHIFT IN BIOLOGICAL SAFETY CABINETS MARKET
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINETS (%)
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS
TABLE 15 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS
5.15 CASE STUDIES
5.15.1 CASE STUDY: LABORATORY BIOLOGICAL SAFETY CABINET (BSC) EXPLOSION
6 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 16 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 17 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (THOUSAND UNITS)
6.2 CLASS I
6.2.1 GOVERNMENT INITIATIVES TO DRIVE MARKET
TABLE 18 CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 CLASS II
TABLE 19 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 20 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 CLASS II TYPE A
6.3.1.1 Increased usage of Class II Type A biosafety cabinets in laboratories to support market growth
TABLE 21 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 CLASS II TYPE B
6.3.2.1 Class II Type B cabinets used for volatile and toxic chemicals
TABLE 22 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 CLASS III
6.4.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 23 CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
7 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER
7.1 INTRODUCTION
TABLE 24 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
7.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
7.2.1 INCREASING R&D EXPENDITURE ENABLES COMPANIES TO INVEST IN HIGH-END BIOSAFETY CABINETS
TABLE 25 BIOLOGICAL SAFETY CABINETS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
7.3 DIAGNOSTIC AND TESTING LABORATORIES
7.3.1 RISING PREVALENCE OF DISEASES TO SUPPORT MARKET GROWTH
TABLE 26 BIOLOGICAL SAFETY CABINETS MARKET FOR DIAGNOSTIC AND TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
7.4 ACADEMIC RESEARCH INSTITUTES
7.4.1 INCREASING NUMBER OF RESEARCH ACTIVITIES AND RISING GOVERNMENT FUNDING FOR MEDICAL RESEARCH TO SUPPORT MARKET GROWTH
TABLE 27 BIOLOGICAL SAFETY CABINETS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
8 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION
8.1 INTRODUCTION
TABLE 28 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET SNAPSHOT
TABLE 29 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Growth in biosimilars market to boost preclinical research
TABLE 33 US: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 34 US: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 35 US: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Government support for R&D to support market growth
TABLE 36 CANADA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 CANADA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 38 CANADA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 39 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 42 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Increased funding and growth of research sector to drive market
TABLE 43 GERMANY: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 GERMANY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 GERMANY: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Increasing awareness about safety in high-risk environments to propel market
TABLE 46 UK: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 UK: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 UK: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing healthcare industry to provide growth opportunities
TABLE 49 FRANCE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 FRANCE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 FRANCE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.4 REST OF EUROPE
TABLE 52 REST OF EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 REST OF EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 REST OF EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET SNAPSHOT
TABLE 55 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Largest market for biological safety cabinets in Asia Pacific
TABLE 59 JAPAN: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 JAPAN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 JAPAN: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Government initiatives in drug development to support market growth
TABLE 62 CHINA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 CHINA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 CHINA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Growing pharmaceutical industry to drive market
TABLE 65 INDIA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 INDIA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 INDIA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 68 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 69 REST OF ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 FAVORABLE GOVERNMENT POLICIES AND INCREASING DEMAND FOR NEW DRUG MOLECULES—KEY FACTORS DRIVING MARKET
TABLE 71 LATIN AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 LATIN AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 LATIN AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST AND AFRICA
8.6.1 INCREASING R&D INVESTMENTS AND FOCUS ON DEVELOPMENT OF NEW DRUGS TO DRIVE MARKET
TABLE 74 MIDDLE EAST AND AFRICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET
TABLE 77 OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOLOGICAL SAFETY CABINET MANUFACTURING COMPANIES
9.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET
9.4 MARKET SHARE ANALYSIS
FIGURE 28 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 78 BIOLOGICAL SAFETY CABINETS MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT
9.5.1 LIST OF EVALUATED VENDORS
9.5.2 STARS
9.5.3 EMERGING LEADERS
9.5.4 PERVASIVE PLAYERS
9.5.5 PARTICIPANTS
FIGURE 29 BIOLOGICAL SAFETY CABINETS MARKET:
COMPETITIVE LEADERSHIP MAPPING, 2021
9.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
FIGURE 30 BIOLOGICAL SAFETY CABINETS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
9.7 COMPETITIVE BENCHMARKING
9.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET
TABLE 79 BIOLOGICAL SAFETY CABINETS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 80 PRODUCT FOOTPRINT OF COMPANIES
TABLE 81 REGIONAL FOOTPRINT OF COMPANIES
TABLE 82 BIOLOGICAL SAFETY CABINETS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
9.8 COMPETITIVE SCENARIO
9.8.1 PRODUCT LAUNCHES
TABLE 83 KEY PRODUCT LAUNCHES
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS
10.1.1 THERMO FISHER SCIENTIFIC
TABLE 84 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.2 KEWAUNEE SCIENTIFIC
TABLE 85 KEWAUNEE SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 33 KEWAUNEE SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.3 LABCONCO
TABLE 86 LABCONCO: BUSINESS OVERVIEW
10.1.4 ESCO MICRO
TABLE 87 ESCO MICRO: BUSINESS OVERVIEW
10.1.5 THE BAKER COMPANY
TABLE 88 THE BAKER COMPANY: BUSINESS OVERVIEW
10.1.6 NUAIRE
TABLE 89 NUAIRE: BUSINESS OVERVIEW
10.1.7 GERMFREE LABORATORIES
TABLE 90 GERMFREE LABORATORIES: BUSINESS OVERVIEW
10.1.8 CRUMA
TABLE 91 CRUMA: BUSINESS OVERVIEW
10.1.9 AIR SCIENCE
TABLE 92 AIR SCIENCE: BUSINESS OVERVIEW
10.1.10 BERNER INTERNATIONAL
TABLE 93 BERNER INTERNATIONAL: BUSINESS OVERVIEW
10.1.11 AZBIL TELSTAR
TABLE 94 AZBIL TELSTAR: BUSINESS OVERVIEW
10.1.12 LABOGENE
TABLE 95 LABOGENE: BUSINESS OVERVIEW
10.1.13 BIOLAB SCIENTIFIC
TABLE 96 BIOLAB SCIENTIFIC: BUSINESS OVERVIEW
10.1.14 LAMSYSTEMS GMBH
TABLE 97 LAMSYSTEMS GMBH: BUSINESS OVERVIEW
10.1.15 FASTER S.R.L.
TABLE 98 FASTER S.R.L.: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 MRC LABORATORY EQUIPMENT
TABLE 99 MRC LABORATORY EQUIPMENT: COMPANY OVERVIEW
10.2.2 NANBEI INSTRUMENT LIMITED
TABLE 100 NANBEI INSTRUMENT LIMITED: COMPANY OVERVIEW
10.2.3 THERMOLAB
TABLE 101 THERMOLAB: COMPANY OVERVIEW
10.2.4 LABMATE
TABLE 102 LABMATE: COMPANY OVERVIEW
10.2.5 TOPAIR SYSTEMS, INC.
TABLE 103 TOPAIR SYSTEMS, INC.: COMPANY OVERVIEW
10.2.6 ALBIAN GROUP
TABLE 104 ALBIAN GROUP: COMPANY OVERVIEW
10.2.7 THOMAS SCIENTIFIC
TABLE 105 THOMAS SCIENTIFIC: COMPANY OVERVIEW
10.2.8 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.
TABLE 106 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
10.2.9 STERICOX
TABLE 107 STERICOX: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
